Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$36.75 USD

36.75
3,121,318

-0.57 (-1.53%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $36.78 +0.03 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Sage Therapeutics (SAGE) Depression Drug Meets Goal, Stock Down

by Zacks Equity Research

Sage Therapeutics (SAGE) and Biogen's (BIIB) depression candidate, zuranolone given along with antidepressants improves depressive symptoms in a phase III study. Questions remain about the durability of the drug.

Zacks Equity Research

AstraZeneca's (AZN) Lupus Drug Saphnelo Gets Europe Nod

by Zacks Equity Research

AstraZeneca's (AZN) Saphnelo is the only new biologic to be approved in Europe in over a decade for patients with systemic lupus erythematosus.

Zacks Equity Research

Baxter (BAX) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Baxter's (BAX) fourth-quarter results reflect robust performance across six of its business units.

Zacks Equity Research

West Pharmaceutical (WST) Q4 Earnings & Revenues Top Estimates

by Zacks Equity Research

West Pharmaceutical's (WST) fourth-quarter earnings reflect strength in the Proprietary Products segment and margin expansion.

Zacks Equity Research

GSK vs. LLY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

GSK vs. LLY: Which Stock Is the Better Value Option?

Zacks Equity Research

Pfizer (PFE) Gets EU Nod for Somatrogon & Pneumococcal Jab

by Zacks Equity Research

Pfizer (PFE) gets approval for pediatric growth hormone deficiency drug, Ngenla (somatrogon) and 20-valent pneumococcal conjugate vaccine, Apexxnar, in Europe.

Zacks Equity Research

Charles River (CRL) Q4 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Robust demand for research models, particularly in China, as well as higher revenues from research model services aid Charles River (CRL) in Q4.

Zacks Equity Research

Alcon's (ALC) Q4 Earnings Top Estimates, Margins Increase

by Zacks Equity Research

According to Alcon (ALC), strong product flow results in above-market revenue growth, which drives core operating leverage and margin expansion.

Zacks Equity Research

Masimo's (MASI) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q4 sales.

Zacks Equity Research

PacBio's (PACB) Q4 Earnings Miss Estimates, Revenues Top

by Zacks Equity Research

PacBio (PACB) sees strength in Q4 segmental revenues, led by robust consumable and instrument sales.

Zacks Equity Research

Ecolab (ECL) Q4 Earnings & Revenues Beat Mark, Margins Down

by Zacks Equity Research

Ecolab's (ECL) robust performance across most of its segments drives its Q4 sales despite business challenges.

Kinjel Shah headshot

Pfizer (PFE) to Ride on COVID Jab & Pill in 2022: What Next?

by Kinjel Shah

Pfizer's (PFE) COVID-19 vaccine and its oral antiviral pill for COVID-19, Paxlovid are expected to generate a combined $54 billion in sales in 2022.

Zacks Equity Research

Are Investors Undervaluing These Medical Stocks Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, AstraZeneca, Glaxo, Sanofi's and Eli Lilly

by Zacks Equity Research

Pfizer, AstraZeneca, Glaxo, Sanofi¿¿¿s and Eli Lilly are highlighted in this Analyst Blog.

Zacks Equity Research

CureVac (CVAC) Begins Influenza Shot Dosing in Phase I Study

by Zacks Equity Research

CureVac (CVAC) doses the first patient in a phase I study with investigational influenza vaccine candidate.

Zacks Equity Research

Lilly (LLY) Gets FDA Panel Advice for New Study on Sintilimab

by Zacks Equity Research

An FDA advisory for Lilly's (LLY) partner Innovent Biologics calls for conducting a new study on its first-line lung cancer candidate, sintilimab, for gaining approval for the same in the United States.

Kinjel Shah headshot

Pharma Stock Roundup: PFE, AZN, GSK's Q4 Earnings, FDA Updates for SNY, LLY

by Kinjel Shah

Pfizer (PFE), AstraZeneca (AZN) and Glaxo (GSK) report fourth-quarter results. FDA approves Sanofi's (SNY) new rare blood disorder drug.

Zacks Equity Research

AstraZeneca (AZN) Q4 Earnings Beat, COVID Vaccine Drives Sales

by Zacks Equity Research

AstraZeneca (AZN) surpasses fourth-quarter estimates for both revenues and earnings. The company issues 2022 guidance

Zacks Equity Research

Glaxo (GSK) Q4 Earnings Top Estimates, Xevudy Adds $1.1B in Sales

by Zacks Equity Research

Glaxo's (GSK) revenues benefit from the recovery in sales of new and specialty drugs, and Consumer Healthcare products along with additional revenues from COVID-19 drug, Xevudy.

Zacks Equity Research

Vir (VIR) Announces Encouraging Data on COVID-19 Antibody

by Zacks Equity Research

Vir (VIR), Glaxo's sotrovimab retains neutralizing activity against the BA.2 subvariant of Omicron, per preclinical data.

Zacks Equity Research

Can Value Investors Select GlaxoSmithKline (GSK) Stock Now?

by Zacks Equity Research

Is GlaxoSmithKline (GSK) a great pick from the value investor's perspective right now? Read on to know more.

Zacks Equity Research

Market Futures Higher Ahead of Opening

by Zacks Equity Research

Market Futures Higher Ahead of Opening

Mark Vickery headshot

Markets Stampede into the Green; CVS, GSK Beat, YUM Mixed

by Mark Vickery

Seeing our economy gaining in growth is a good reason for investors to become a little less risk-averse.

Indrajit Bandyopadhyay headshot

Glaxo (GSK) Beats Earnings and Revenues Estimates in Q4

by Indrajit Bandyopadhyay

Glaxo (GSK) beats earnings as well as revenues estimates in the fourth quarter of 2021. Stock down.

Zacks Equity Research

Is GlaxoSmithKline (GSK) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how GlaxoSmithKline (GSK) and Vertex Pharmaceuticals (VRTX) have performed compared to their sector so far this year.